Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-B01D1 + MRTX1719 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-B01D1 | BL B01D1|BLB01D1|BMS986507|BMS 986507|BMS-986507|Izalontamab brengitecan | EGFR Antibody 81 HER3 (ERBB3) Antibody 30 | BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (PMID: 38823410). | |
| MRTX1719 | MRTX-1719|MRTX 1719|BMS 986504|BMS986504|BMS-986504|BMS986504|Navlimetostat | PRMT5 Inhibitor 21 | MRTX1719 inhibits the PRMT5-MTA complex, which potentially results in reduced tumor growth (PMID: 35041419). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06855771 | Phase II | MRTX1719 BL-B01D1 + MRTX1719 | A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) | Recruiting | USA | SWE | ROU | POL | ITA | GBR | FRA | ESP | DEU | AUS | 2 |